RealWtLoss

It is clear that semaglutide medications improve the outcomes some of the cardiovascular outcomes of obese type 2 diabetics.  It now appears that this is also true for those with obesity and existing cardiovascular disease (at least for 2.4 mg weekly for 48 weeks).

In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. 


As expected, the semaglutide patients experienced higher gastrointestinal symptoms compared to placebo, leading to a higher discontinuance percentage.